Read the letters we sent to Fox Broadcasting and the Food and Drug Administration explaining our concerns with the Hims & Hers Super Bowl ad, which promoted compounded weight loss injectables without mentioning their potential risks or side effects
In obesity trials, retatrutide has produced average weight loss of up to 24.2% at 48 weeks , 28.7% at 68 weeks , and 28.3% at 80 weeks , depending on the trial, dose and study population
doi:10.1016/j.ejmech.2016.10.044 29
You should seek prompt medical advice if you are currently using unlicensed peptides and experience any of the following: Persistent nausea, vomiting, or severe abdominal pain (which may indicate pancreatitis) Unexplained changes in heart rate or palpitations Symptoms of hypoglycaemia , such as shakiness, sweating, confusion, or dizziness Injection site redness, swelling, or signs of infection Unusual lumps, swelling in the neck, or difficulty swallowing (which may indicate thyroid changes) Mood changes, anxiety, or psychological distress related to body image or supplement use For urgent medical advice, contact NHS 111 (online at 111.nhs.uk or by telephone)
You may need to restart titration from a lower dose to avoid GI side effects when re-introducing the drug
Youll likely see improvements in liver enzyme tests before structural changes occur
